Paycom Software, Inc. Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired the publicly traded securities of Paycom Software, Inc. (“Paycom” or the “Company”) (NYSE: PAYC) securities between May 3, 2023 and November 1, 2023, inclusive (the “Class Period”). … Read More
Spectrum Pharmaceuticals, Inc. Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a proposed class action suit in the United States District Court for the Southern District of New York against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NasdaqGS: SPPI), Thomas J. Riga, the Company’s Chief Executive Officer, and a member of the Company’s Board of Directors, Francois J. Lebel, the Company’s Chief Medical Officer, and Nora E. Brennan, the Company’s Chief Financial Officer. … Read More
Co-Diagnostics, Inc. Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the Southern District of New York against Co-Diagnostics, Inc. (“Co-Dx” or the “Company”) (NASDAQ: CODX); Dwight H. Egan, the Company’s Chief Executive Officer, President and Chairman of the Board; and Brian L. Brown, the Company’s Chief Financial Officer and Secretary (“Defendants”)…. Read More
Bayer “One-A-Day” Vitamin Consumer Class Action In conjunction with the Center for Science in the Public Interest, Kaplan Fox is co-counsel for the plaintiffs in this consumer protection class action, alleging that Bayer AG and its US subsidiaries have falsely marketed various “One-A-Day” vitamin supplements. The complaint alleges that Bayer improperly touts unsupported claims of “heart health,” “immunity support,” and “energy” benefits that mislead consumers. On March 10, 2015, the Northern District of California denied portions of Bayer’s motion to dismiss, allowing the case to proceed…. Read More
